Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study
PaperCitations, authors & open-access status
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 160 citations, 2022 year and hybrid oa status.
160
Citations
2022
Year
hybrid
OA Status